Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A hoosier oncology group trial, HEM01-21

Attaya Suvannasankha, Christopher Fausel, Beth E. Juliar, Constantin T. Yiannoutsos, William B. Fisher, Rafat H. Ansari, Lisa L. Wood, Gina G. Smith, Larry D. Cripe, Rafat Abonour

Research output: Contribution to journalArticle

43 Scopus citations

Abstract

Thalidomide has direct antimyeloma and immunomodulatory effects. In addition, both thalidomide and metronomic chemotherapy inhibit angiogenesis. The synergy of such a combination may decrease toxicity while maintaining efficacy. The Hoosier Oncology Group conducted a phase II trial of oral cyclophosphamide (50 mg b.i.d. for 21 days), thalidomide (200 mg/day), and prednisone (50 mg q.o.d.) (CTP) per 28-day course in patients with relapsed multiple myeloma (MM). Of the 37 patients enrolled, 16 had prior stem cell transplantation. The median follow-up time was 25.3 months (95% confidence interval [CI] 23.2-27.7). Of 35 patients treated, 22 patients (62.9%) responded: 7 (20.0%) complete responses, 2 (5.7%) near-complete responses, and 13 (37.1%) partial responses. Eight patients (22.9%) had stable disease, and three (8.6%) had disease progression. Two patients withdrew from the study early due to reasons unrelated to progression or toxicity and were treated as nonresponders. The median time to best response and time to progression were 3.6 months (95% CI 2.8-10.9) and 13.2 months (95% CI 9.4-21.0), respectively. The median number of treatment cycles was seven (range 1-12 cycles). Grade III to IV toxicities included leukopenia (42.9%; febrile neutropenia, 11.4%), hyperglycemia (20%), sensory neuropathy (11.4%), thromboses (8%), and motor neuropathy (5.7%). No patient withdrew from the study due to toxicity. The efficacy and low toxicity of the CTP regimen support the future development of such an approach in MM.

Original languageEnglish (US)
Pages (from-to)99-106
Number of pages8
JournalOncologist
Volume12
Issue number1
DOIs
StatePublished - Jan 29 2007

Keywords

  • Antineoplastic-combined chemotherapy protocols
  • Cyclophosphamide
  • Dexamethasone
  • Multiple myeloma
  • Oral administration
  • Salvage therapy
  • Thalidomide

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Fingerprint Dive into the research topics of 'Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A hoosier oncology group trial, HEM01-21'. Together they form a unique fingerprint.

  • Cite this